title: [Cytology and DNA HPV-testing in the era of HPV-vaccine].
abstract: Human papillomavirus (HPV) persistent infection is the main factor leading to the cervical cancer carcinogenesis. Wide-spread public vaccination against HPV as primary prevention is expected to reduce cervical cancer incidence and mortality rates. It is essential to bear in mind that screening for precancerous lesions cannot be discontinued because vaccination will not protect the patients against HPV types which have not been included in the first and second generation of vaccines.
authors.affiliation: Klinika Onkologii Ginekologicznej Katedry Ginekologii i Połoznictwa Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu. ptgms@gpsk.am.poznan.pl
authors.forename: Marek
authors.initials: M
authors.lastname: Spaczyński
authors.forename: Blanka
authors.initials: B
authors.lastname: Malkowska-Walczak
authors.forename: Ewa
authors.initials: E
authors.lastname: Nowak-Markwitz
mesh_terms: D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000235:genetics / Q000276:immunology*; D004279:DNA, Viral / Q000302:isolation & purification*; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D015229:Sexually Transmitted Diseases, Viral / Q000517:prevention & control / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology*; D014611:Vaccination
chemical_list: D004279:DNA, Viral; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines